Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Brain Cancer
Multidisciplinary Teamwork in Guiding Treatment Decisions and Management of Patients Undergoing Surgery or Radiation for Intracranial Tumors
Primary and metastatic brain tumors are a heterogeneous group of neoplasms with varied outcomes and management strategies. CNS tumors are associated with a range of symptoms and complications such as edema, seizures, endocrinopathy, fatigue, psychiatric disorders, and venous thromboembolism that can seriously impact patients’ quality of life. These symptoms and complications can be related to the presence or progression of the disease but also can be caused or worsened by treatment – either due to damage to healthy tissues and structures or due to the destruction of the tumor itself. Predicting whether a particular treatment will improve a patient’s quality of life is not a trivial endeavor. Because of this marked heterogeneity and wide range of serious and debilitating symptoms and complications, clinicians need to carefully review the prognostic features and treatment options for brain tumors on an individual basis and sensitively communicate these to each patient. It is important for clinicians to recognize that involvement of an interdisciplinary team, including neurosurgeons, radiation therapists, oncologists, neurologists, and/or neuroradiologists, is a key factor in the appropriate management of these patients.
This educational program is designed to meet the educational needs of physicians, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Explain to patients the differences between resection, stereotactic radiosurgery (SRS), fractionated stereotactic radiation therapy, and whole-brain radiation therapy, in terms of treatment administration, efficacy, and potential impacts on cognitive function, symptoms, and quality of life.
- Describe the phenomenon of brain tumor pseudoprogression and its impact on patient management.
- List common symptoms and functional problems that can be caused by brain tumors or brain tumor treatment, and explain to patients the options for management of each of these.
Ian Parney, MD, PhD
Mayo Clinic Cancer Center
Paul Brown, MD
Mayo Clinic Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below discloses no relevant financial relationships:
Ian Parney, MD, PhD
The faculty listed below disclose the following relevant financial relationships:
Paul Brown, MD
Novella Clinical – DSMB Member
UpToDate - Contributor
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kim Bayer; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Melinda Somasekhar, PhD (employed by NCCN until October 30, 2017)
The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Donald Harting, ELS, CHCP
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options
Boston Scientific Corporation – Equity Interest/Stock Options
Pfizer Inc. – Equity Interest/Stock Options
The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Susan Darlow, PhD
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category 1 credit for completing this activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00032912; Approval #: 180002594
|National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-18-093-L01-P
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing